Chiu Annie, Mariwalla Kavita, Hui-Austin Andrea, Narurkar Vic, de la Guardia Carola
J Drugs Dermatol. 2019 Jul 1;18(7):633-641.
Background: As facial aesthetic procedures have become more widely accepted, the racial and ethnic diversity of aesthetic patient populations has increased. Asian Americans represent a growing segment of this population and have specific aesthetic concerns that should be differentiated from the broader Caucasian population. Objective: An online study was designed to survey facial aesthetic concerns, treatment priorities, and future treatment considerations among a US-based population of Asian American women. Materials and Methods: A total of 403 participants ages 30 to 65 years reported perspectives on facial aging, current facial conditions, most bothersome facial areas, most/least likely to be treated first, awareness of treatment options and consideration rates, and motives/barriers impacting the consideration rate of injectable treatments. Results: Treatment interests reflected predominant issues; uneven skin tone, wrinkles, and sun damage. Most bothersome facial areas included the periorbital area, forehead, and submental area, and also among areas designated as most likely to treat first. The majority of participants would consider injectables. However, safety/side effects, cost, and concerns about not looking natural were primary barriers. Conclusion: Understanding the aesthetic concerns and priorities specific to Asian American women may help guide treatment plans more aligned with the goals and expectations of this patient population. J Drugs Dermatol. 2019;18(7):633-641.
随着面部美容手术越来越被广泛接受,美容患者群体的种族和民族多样性有所增加。亚裔美国人在这一群体中所占比例日益增大,他们有一些特定的美容问题,应与更广泛的白人群体区分开来。目的:设计一项在线研究,以调查美国亚裔美国女性群体对面部美容问题、治疗优先级以及未来治疗考虑因素的看法。材料与方法:共有403名年龄在30至65岁之间的参与者报告了对面部衰老、当前面部状况、最困扰的面部区域、最先治疗的最可能/最不可能部位、对治疗选择的知晓度和考虑率,以及影响注射治疗考虑率的动机/障碍。结果:治疗兴趣反映了主要问题;肤色不均、皱纹和阳光损伤。最困扰的面部区域包括眶周区域、前额和颏下区域,也是最先治疗的最可能部位。大多数参与者会考虑注射治疗。然而,安全性/副作用、成本以及对看起来不自然的担忧是主要障碍。结论:了解亚裔美国女性特有的美容问题和优先级可能有助于制定更符合该患者群体目标和期望的治疗方案。《药物皮肤病学杂志》。2019年;18(7):633 - 641。